论文部分内容阅读
目的 :检测微卫星不稳定性 (MSI)与非小细胞肺癌 (NSCL C)临床分期的关系。 方法 :采用聚合酶链反应扩增 ,变性聚丙烯酰胺凝胶电泳等技术 ,分别选用定位于 X及 2 1号染色体的 AR和 UT76 2 微卫星标记位点 ,对 30例 NSCL C标本作 MSI测定。所有 NSCL C分期均采用国际抗癌联盟 1989年分期标准。 结果 :AR位点 MSI阳性 7例 (2 3% ) ,U T76 2 位点阳性 6例(2 0 % )。总阳性病例 13例 (43% )。早期 ( 期、 期 11例 ) 9例阳性 (82 % ) ,晚期 ( a期、 b期 19例 ) 4例阳性 (2 1% ) ,两者阳性率有显著性差异 (P<0 .0 1)。 结论 :MSI为早期 NSCL C的重要标志之一 ,对其预后判断有一定指导意义。
Objective: To examine the relationship between microsatellite instability (MSI) and clinical stage of non-small cell lung cancer (NSCL C). Methods: Polymerase chain reaction (PCR) amplification and denaturing polyacrylamide gel electrophoresis were used to detect MSI of 30 NSCL C specimens by using AR and UT76 2 microsatellite loci located on chromosome X and chromosome 21, respectively . All NSCL C staging uses the International Union Against Cancer 1989 phased standard. Results: Seven cases (23%) were MSI positive at AR site and 6 cases (20%) were positive at U T76 2 site. Total positive cases in 13 cases (43%). There were 9 positive cases (82%) in the early stage (11 cases) and 4 cases (2 1%) in the late stage (stage a and b), the positive rates were significantly different between the two groups (P <0.01) ). Conclusion: MSI is one of the most important markers of early stage NSCL C, which may be of guiding significance for its prognosis.